

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 JUNE 2023

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the annual general meeting (the “**AGM**”) of Kintor Pharmaceutical Limited (the “**Company**”) both dated 15 May 2023. Unless otherwise defined herein, the capitalised terms used herein shall have the same meaning as those defined in the Circular.

POLL RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held on 15 June 2023, all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll.

As at the date of the AGM, the total issued share capital of the Company comprises 447,499,600 Shares. In accordance with Rule 17.05A of the Listing Rules, Kiya Company Limited (a company incorporated by the trustee of the Company’s employee incentive scheme to hold Shares for the benefit of the employees) abstained from voting at the AGM with respect to 17,975,542 unvested Shares held by it. Accordingly, the total number of Shares entitling the Shareholders to attend and vote at the AGM was 429,524,058. Save as disclosed above, (i) there were no restrictions on any Shareholders of the Company to cast votes on any of the proposed resolutions at the AGM; and (ii) no Shareholder was required under the Listing Rules to abstain from voting on any of the resolutions proposed at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules, and none of the Shareholders have stated their intention in the Circular to vote against or abstain from voting on any of the proposed resolutions at the AGM.

All of the Directors attended the AGM. The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM. The poll results in respect of all the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of votes cast (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “ Director(s) ”) and independent auditor for the year ended 31 December 2022.	128,521,120 (99.99%)	10,000 (0.01%)
2.	(a) (i) To re-elect Dr. Qun LU as an executive Director.	128,507,864 (99.98%)	23,256 (0.02%)
	(ii) To re-elect Dr. Xiang NI as an executive Director.	128,507,864 (99.78%)	283,256 (0.22%)
	(iii) To re-elect Dr. Michael Min XU as an independent non-executive Director.	128,488,090 (99.97%)	43,030 (0.03%)
	(iv) To re-elect Mr. Wallace Wai Yim YEUNG as an independent non-executive Director.	128,488,090 (99.97%)	43,030 (0.03%)
	(v) To re-elect Prof. Liang TONG as an independent non-executive Director.	128,521,120 (99.99%)	10,000 (0.01%)
	(b) To authorise the board of Directors (the “ Board ”) to fix the remuneration of the Directors.	128,521,120 (99.99%)	10,000 (0.01%)
3.	To re-appoint Messrs. PricewaterhouseCoopers as the auditor of the Company until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix its remuneration.	128,521,120 (99.99%)	10,000 (0.01%)

Ordinary Resolutions		Number of votes cast (%)	
		For	Against
4.	(A) To give a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the total number of issued shares of the Company.	121,035,029 (94.17%)	7,496,091 (5.83%)
	(B) To give a general mandate to the Directors to repurchase shares not exceeding 10% of the total number of issued shares of the Company.	128,521,120 (99.99%)	10,000 (0.01%)
	(C) To extend the authority given to the Directors pursuant to ordinary resolution no. 4(A) to issue shares by adding to the number of issued shares of the Company the number of shares repurchased under ordinary resolution no. 4(B).	121,035,029 (94.17%)	7,496,091 (5.83%)
5.	To consider and approve the increase of the authorised share capital of the Company from US\$50,000 divided into 500,000,000 shares to US\$70,000 divided into 700,000,000 shares of US\$0.0001 each by the creation of an additional US\$20,000 divided into 200,000,000 shares of US\$0.0001 each.	128,521,120 (99.99%)	10,000 (0.01%)
Special Resolutions		Number of votes cast (%)	
		For	Against
6.	Subject to the passing of resolution no. 5, to consider and approve the proposed amendments to the memorandum of association of the Company and to adopt the new memorandum of association of the Company.	128,521,120 (99.99%)	10,000 (0.01%)
7.	To consider and approve the proposed amendments to the articles of association of the Company and to adopt the new articles of association of the Company.	128,521,119 (99.99%)	10,001 (0.01%)

For details of the above resolutions, please refer to the Circular.

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions numbered 1 to 5, all of the above ordinary resolutions were duly passed as ordinary resolutions of the Company. As more than 75% of the votes were cast in favour of the above special resolutions numbered 6 and 7, both of the above special resolutions were duly passed as special resolutions of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 15 June 2023

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*